Are You Leveraging the Drug Discovery and Early Development Outsourcing Services Ecosystem to Accelerate Growth?
Frost & Sullivan
MARCH 22, 2024
However, the pharma/biopharma industry shows overall stagnant R&D activity. Small-to-mid and emerging biopharma players contribute over 16%. How are drug discovery companies enhancing R&D and accelerating growth through ecosystem partnerships? increase from 2022. Total R&D expenditure is approximately $276.81
Let's personalize your content